![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
A Berson, C Wolf, C Chachaty, C Fisch, D Fau, D Eugene, J Loeper, JC Gauthier, P Beaune and D Pompon
Institut National de la Sante et de la Recherche Medicale (INSERM) U- 24, Hopital Beaujon, Clichy, France.
The in vitro metabolic activation of flutamide, a nitroaromatic antiandrogen which produces hepatitis in a few recipients, was first studied with male rat liver microsomes. There was no electron spin resonance evidence for the reduction of flutamide by reduced nicotinamide adenine dinucleotide phosphate (NADPH)-cytochrome P-450 reductase into a nitro anion free radical. In contrast, flutamide was oxidatively transformed by cytochrome P-450 into reactive metabolite(s) that covalently bound to microsomal proteins. Covalent binding required oxygen and NADPH, and was decreased by the nucleophile glutathione and by the cytochrome P-450 inhibitors SKF 525-A, piperonyl butoxide and troleandomycin (an inhibitor of the cytochrome P-450 3A subfamily). Covalent binding was increased markedly by pretreatment with dexamethasone (an inducer of the cytochrome P-450 3A subfamily) and moderately by pretreatment with beta-naphthoflavone (an inducer of the 1A family). Covalent binding was immunoinhibited markedly by anticytochrome P-450 3A immunoglobulin G and moderately by anticytochrome P-450 1A immunoglobulin G. Covalent binding was much lower with liver microsomes from female rats (not expressing P-450 3A2). Covalent binding of flutamide also occurred with human liver microsomes (where it was inhibited by troleandomycin), and with yeast microsomes expressing human liver cytochromes P-450 1A1, 1A2 or 3A4. We concluded that flutamide was oxidatively transformed into chemically reactive metabolite(s) by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies.
This article has been cited by other articles:
|
|
 |
|
  K. Mizuno, M. Katoh, H. Okumura, N. Nakagawa, T. Negishi, T. Hashizume, M. Nakajima, and T. Yokoi Metabolic Activation of Benzodiazepines by CYP3A4 Drug Metab. Dispos., February 1, 2009; 37(2): 345 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Sjogren, H. Lennernas, T. B. Andersson, J. Grasjo, and U. Bredberg The Multiple Depletion Curves Method Provides Accurate Estimates of Intrinsic Clearance (CLint), Maximum Velocity of the Metabolic Reaction (Vmax), and Michaelis Constant (Km): Accuracy and Robustness Evaluated through Experimental Data and Monte Carlo Simulations Drug Metab. Dispos., January 1, 2009; 37(1): 47 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ohbuchi, M. Miyata, D. Nagai, M. Shimada, K. Yoshinari, and Y. Yamazoe Role of Enzymatic N-Hydroxylation and Reduction in Flutamide Metabolite-Induced Liver Toxicity Drug Metab. Dispos., January 1, 2009; 37(1): 97 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kang, D. Dalvie, E. Smith, S. Zhou, A. Deese, and J. A. Nieman Bioactivation of Flutamide Metabolites by Human Liver Microsomes Drug Metab. Dispos., July 1, 2008; 36(7): 1425 - 1437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kang, D. Dalvie, E. Smith, S. Zhou, and A. Deese Identification of a Novel Glutathione Conjugate of Flutamide in Incubations with Human Liver Microsomes Drug Metab. Dispos., July 1, 2007; 35(7): 1081 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Coe, S. D. Nelson, R. G. Ulrich, Y. He, X. Dai, O. Cheng, M. Caguyong, C. J. Roberts, and J. G. Slatter PROFILING THE HEPATIC EFFECTS OF FLUTAMIDE IN RATS: A MICROARRAY COMPARISON WITH CLASSICAL ARYL HYDROCARBON RECEPTOR LIGANDS AND ATYPICAL CYP1A INDUCERS Drug Metab. Dispos., July 1, 2006; 34(7): 1266 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Berson, S. Cazanave, V. Descatoire, M. Tinel, A. Grodet, C. Wolf, G. Feldmann, and D. Pessayre The Anti-Inflammatory Drug, Nimesulide (4-Nitro-2-phenoxymethane-sulfoanilide), Uncouples Mitochondria and Induces Mitochondrial Permeability Transition in Human Hepatoma Cells: Protection by Albumin J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 444 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Goda, D. Nagai, Y. Akiyama, K. Nishikawa, I. Ikemoto, Y. Aizawa, K. Nagata, and Y. Yamazoe DETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTS Drug Metab. Dispos., May 1, 2006; 34(5): 828 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Obligacion, M. Murray, and I. Ramzan Drug-Metabolizing Enzymes and Transporters: Expression in the Human Prostate and Roles in Prostate Drug Disposition J Androl, March 1, 2006; 27(2): 138 - 150. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Shet, M. McPhaul, C. W. Fisher, N. R. Stallings, and R. W. Estabrook Metabolism of the Antiandrogenic Drug (Flutamide) by Human CYP1A2 Drug Metab. Dispos., November 1, 1997; 25(11): 1298 - 1303. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
